News and Announcements
OncoPac Global Clinical Study Receives Ethics Approval from Monash Health
- Published February 02, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX: OSL) is a medical device company that focuses on localised treatments for patients with pancreatic and liver cancer. The Company are pleased to announce that they have been granted the Ethical Approval from the Monash Health for its OncoPac global clinical study program that is specialised for pancreatic cancer.
This study will provide a significant clinical study process to date. The Ethics Approval at Monash Health will also facilitate ethics approval for other participating study centres Australia-wide (excluding Western Australia); this in turn will help accelerate the patient recruitment process.
The success of this grant taking place at Monash Health comes after the Company filed its Ethics Committee (HREC) submission during November last year. Monash Health is the largest public health service in Melbourne, that has agreed to lead this Australian study. Monash provides health care services to over 1.5million people per year. This particular health care facility has also be named one of Victoria’s premier cancer facilities.
To date, OncoSil Medical has confirmed the participation of 12 centres for its global pancreatic clinical study program, along with currently being involved in further discussion with seven centres in the UK, Europe and Australia. The Company, will soon start adding new centres to its trail program in the coming months, along with commencing patient recruitment globally.
OnocSil Medical will update the market on the progress of the OncoPaC clinical study program in due course.
OncoSil Chief Executive Officer, Daniel Kenny commented:
“We are extremely pleased to have secured Ethics Approval for our global OncoPaC clinical study program in pancreatic cancer at Monash Health. Monash is a highly regarded cancer centre and is also the lead Australian centre for our clinical study program. With Ethics Approval granted at Monash, it now paves the way for the provision of ethics approvals across other Australian study centres, a pivotal requirement in the study program.”
To view the full announcement, please click here.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
